ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 556 • 2014 ACR/ARHP Annual Meeting

    Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations

    Marie Godfrin-Valnet1, Marc Puyraveau2 and Daniel Wendling3, 1Rheumatology, CHRU, Besançon, France, 2Investigation Center, CHRU, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France

    Background/Purpose: Spondyloarthritis (SpA) activity varies with time and treatment, but to date no clear definition of a flare of the disease is available. The aim…
  • Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting

    Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment

    Ronald F. van Vollenhoven1, Rebecca J. Bolce2, Karen Hambardzumyan3, Saedis Saevarsdottir4, Kristina Forslind4, Ingemar Petersson5, Eric H. Sasso2, CC Hwang6, Oscar Segurado2 and Pierre Geborek7, 1Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3ClinTRID, the Karolinska Institute, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, 6Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, 7Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

    Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
  • Abstract Number: 2911 • 2014 ACR/ARHP Annual Meeting

    Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?

    Tuulikki Sokka1, Hannu Kautiainen2, Tuomas Rannio3, Juha Asikainen1 and Pekka Hannonen1, 1Jyvaskyla Central Hospital, Jyväskylä, Finland, 2Medcare Oy, Äänekoski, Finland, 3Kuopio University Hospital, Kuopio, Finland

     Background/Purpose: Early vs. delayed referral/start of therapy within 3-4 months has been shown beneficial for outcomes in rheumatoid arthritis (RA) (Lard et al. AM J…
  • Abstract Number: 2547 • 2014 ACR/ARHP Annual Meeting

    The Impact of Primary Sjögren’s Syndrome on Female Sexual Function

    Jolien F. van Nimwegen1, Suzanne Arends1, Greetje S. van Zuiden1, Arjan Vissink2, Frans G.M. Kroese1 and Hendrika Bootsma1, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

    Background/Purpose . Primary Sjögren's syndrome (pSS) is a chronic and disabling disease, characterized by sicca symptoms of the eyes and mouth as well as fatigue.…
  • Abstract Number: 2135 • 2014 ACR/ARHP Annual Meeting

    Patients with Moderate Disease Activity in the First 5 Years of Rheumatoid Arthritis Still Progress Radiographically Despite Conventional Disease Modifying Therapy

    Lewis Carpenter1, Elena Nikiphorou2, Sam Norton3, Keeranur Jayakumar4, Josh Dixey5 and Adam Young6, 1Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, 2School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3Institute of Psychiatry, King's College London, London, United Kingdom, 4Rheumatology, Heart of England NHS Foundation Trust, Birmingham, United Kingdom, 5Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, 6Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom

    Background/Purpose:  Patients with moderate disease are an important, and often poorly studied, patient subgroup. The extent to which traditional DMARD therapies adequately control the disease…
  • Abstract Number: 1593 • 2014 ACR/ARHP Annual Meeting

    Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis

    Vinod Chandran1, Arane Thavaneswaran2 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. There are few biomarkers for disease activity in PsA. Traditional acute phase reactants are…
  • Abstract Number: 1314 • 2014 ACR/ARHP Annual Meeting

    Comparison of the Utility and Validity of Three Scoring Tools to Detect Skin Disease in Patients with Juvenile Dermatomyositis

    Raquel Campanilho-Marques1, Beverley Almeida2, Katie Arnold1, Kiran Nistala3, Clarissa A Pilkington4 and Lucy R Wedderburn1, 1Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, 2Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 3Centre for Rheumatology, University College London, London, United Kingdom, 4Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare condition affecting 3 children/million/year. Muscle and skin involvement are key features. The muscle symptoms are frequently the main…
  • Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting

    The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?

    Elena Myasoedova1, Arun K. Chandran2, Birkan İlhan3, Brittny T. Major4, C. John Michet III2, Eric L. Matteson2 and Cynthia S. Crowson4, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, 4Health Sciences Research, Mayo Clinic, Rochester, MN

    Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
  • Abstract Number: 488 • 2014 ACR/ARHP Annual Meeting

    Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis

    Joel M. Kremer1, Mark C Genovese2, Edward C. Keystone3, Peter C. Taylor4, Steven H. Zuckerman5, Douglas E. Schlichting5, Eric P. Nantz5, Scott D. Beattie5 and William L. Macias6, 1Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 2Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, 3University of Toronto, Toronto, ON, Canada, 4NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, 5Eli Lilly and Company, Indianapolis, IN, 6Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Treatment with baricitinib (bari), an oral inhibitor of JAK1/JAK2, demonstrated improvements in signs and symptoms of RA through 52 wks in a Phase 2b…
  • Abstract Number: 356 • 2014 ACR/ARHP Annual Meeting

    The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis

    Lena Bugge Nordberg1, Elisabeth Lie2, Anna-Birgitte Aga1, Marthe Thoresen Maehlen3, Inge Olsen C4, Till Uhlig4, Tore K. Kvien4, Espen A. Haavardsholm5 and the Arctic study Group5, 1Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Department of rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Diakonhjemmet Hospital, Oslo, Norway

     Background/Purpose: The Rheumatoid arthritis impact of disease (RAID) score is a relatively new patient-derived composite score assessing the seven most important domains of the impact…
  • Abstract Number: 2569 • 2013 ACR/ARHP Annual Meeting

    Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis

    Michal Tomcik1, Lucie Andres Cerezo1, Simona Skacelova2, Martin Komarc3, Radim Becvar1, Mariam Grigorian4, Joerg HW Distler5 and Ladislav Senolt1, 1Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 3Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic, 4Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark, 5Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Our previous study demonstrated that S100A4 is overexpressed in scleroderma (SSc) skin, fibroblasts and preclinical models of SSc in a TGF-β dependent manner. Furthermore,…
  • Abstract Number: 2251 • 2013 ACR/ARHP Annual Meeting

    Variability in the Classification of Remission Among Disease Activity Indices and Their Correlation: An Analysis From a  Prospective, Observational Registry

    William G. Bensen1, Algis V Jovaisas2, J. Carter Thorne3, Philip Baer4, Majed M. Khraishi5, Sanjay Dixit6, Denis Choquette7, Michael Starr8, Isabelle Fortin9, Dalton E. Sholter10, Emmanouil Rampakakis11,12, John S. Sampalis11,12, Francois Nantel13, Allen J. Lehman14, May Shawi15 and Susan M. Otawa14, 1Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 2Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Southlake Regional Health Centre, Newmarket, ON, Canada, 4Private Practice, Scarborough, ON, Canada, 5Nexus Clinical Research, St John's, NF, Canada, 6McMaster University, Hamilton, ON, Canada, 7Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 8Montreal General Hospital, Montreal, QC, Canada, 9Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 10Rheumatology Associates, Edmonton, AB, Canada, 11JSS Medical Research, Montreal, QC, Canada, 12Jewish General Hospital, McGill University, Montreal, QC, Canada, 13Janssen Inc., Toronto, ON, Canada, 14Medical Affairs, Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada

    Background/Purpose: In recent years, disease remission in rheumatoid arthritis (RA) has been assessed using various disease activity indices such as the DAS28-CRP, SDAI, CDAI, ACR/EULAR-recommended…
  • Abstract Number: 1779 • 2013 ACR/ARHP Annual Meeting

    A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis

    Li Alemo Munters1,2, Ingela M. Loell3, Joan Raouf4, Maryam Dastmalchi3, Eva Lindroos5, Christina Ottosson6, Yi-Wen Chen7, Annemarie F van Delden8, Mona Esbjörnsson9, Marina Korotkova10, Helene Alexanderson11, Kanneboyina Nagaraju12 and Ingrid E. Lundberg13, 1Department of Medicine, Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 2Department of Physiotherapy, Rheumatology Unit, Karolinska University Hospital in Solna, Stockholm, Sweden, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 5Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 6Department of Medicine, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 7Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, 8Department of Medicine,, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 9Department of Physiology, Karolinska Institutet, Huddinge, Sweden, 10Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 11Department of Neurobiology, Care Science and Society, Division of Physiotherapy, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, 12Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, 13Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: This pilot study is a hypothesis-driven exploratory part of a larger randomized controlled trial evaluating effects of a supervised 12-week endurance exercise program (EG)…
  • Abstract Number: 1359 • 2013 ACR/ARHP Annual Meeting

    Does Rheumatoid Arthritis Disease Activity Correlate With Weather Conditions?

    Eimear Savage1, David McCormick1, Stephen McDonald1, Michael Stevenson2, Owen Moore3 and Andrew Cairns4, 1Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, 2Medical Statistics, Centre for Public Health., Queens University, Belfast. School of Medicine, Dentistry and Biomedical Sciences., Belfast BT12 6BJ, Northern Ireland, 3Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, 4Rheumatology, Belfast Hospitals Trust, Musgrave Park Hospital, Belfast, United Kingdom

    Background/Purpose: Rheumatoid Arthritis is a common inflammatory joint condition affecting up to 1% of the Northern Ireland population.  Patients often report increasing joint pain with…
  • Abstract Number: 942 • 2013 ACR/ARHP Annual Meeting

    CXCL13 Is a Marker Of Joint Involvement In Early Rheumatoid Arthritis

    Stinne Greisen1, Tue Rasmussen1, Karen Schelde1, Kristian Stengaard-Pedersen2, Merete Lund Hetland3, Kim Hørslev-Petersen4, Bent Deleuran5 and Malene Hvid6, 1Dept of Biomedicine, Aarhus University, Aarhus, Denmark, 2Arhus University Hospital, Aarhus, Denmark, 3Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 4Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Background/Purpose: CXCL13 is central in the formation of lymphoid follicles in secondary and tertiary lymphoid tissue. It attracts CXCR5-expressing B cells and follicular helper T…
  • « Previous Page
  • 1
  • …
  • 93
  • 94
  • 95
  • 96
  • 97
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology